Term
Duloxetine HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Potent inhibitors of 5HT and NE and weak inhibitor of DA reuptake |
|
|
Term
Venlafaxine HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Potent inhibitors of 5HT and NE and weak inhibitor of DA reuptake |
|
|
Term
Sertraline HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Inhibition of CNS neuronal uptake of 5HT and weak action on NE & DA |
|
|
Term
Trazodone HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Inhibits 5HT reuptake by brain synaptosomes therefore increasing the behavioral effects of 5HT PRECURSOR 5-OH-tryptophan |
|
|
Term
Citalopram HBr
Pharmacology/Pharmacokinetics |
|
Definition
| Blocks the neuronal uptake of 5HT into human platelets in the CNS |
|
|
Term
Amitriptyline HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Inhibits the membrane pump mechanism responsible for the reuptake of NE & 5HT at the presynaptic nerve terminals |
|
|
Term
Bupropion HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Weak inhibitor of 5HT, NE, & DA, but not MAO |
|
|
Term
Escitalopram Oxalate
Pharmacology/Pharmacokinetics |
|
Definition
| Blocks neuronal uptake of 5HT |
|
|
Term
Fluoxetine HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Blocks the neuronal uptake of 5HT into human platelets in the CNS |
|
|
Term
Aripiprazole
Pharmacology/Pharmacokinetics |
|
Definition
Partial agonist D2 & 5HT1A
Antagonist 5HT2A |
|
|
Term
Donepezil HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Reversible AChE inhibitor that works centrally to increase the amt of ACh |
|
|
Term
Quetiapine Fumerate
Pharmacology/Pharmacokinetics |
|
Definition
| Antagonist at 5HT1A, 5HT2, D1, D2, H1, adrenergic alpha-1, and alpha-2 |
|
|
Term
Risperidone
Pharmacology/Pharmacokinetics |
|
Definition
| Antagonist at D2, 5HT2, H1, adrenergic alpha-1, and alpha-2 |
|
|
Term
Pregabalin
Pharmacology/Pharmacokinetics |
|
Definition
| High binding affinity to alpha2-delta; increase the density of GABA transporter ptn & increase the rate of functional GABA transport |
|
|
Term
Lamotrigine
Pharmacology/Pharmacokinetics |
|
Definition
| inhibition of voltage-sensitive Na channels resulting in a stabilization of neuronal membranes & modulation of presynaptic transmitter release of excitatory aas (glutamate & aspartate) |
|
|
Term
Gabapentin
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Clonazepam
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Topiramate
Pharmacology/Pharmacokinetics |
|
Definition
1. AP elicited repetitively by a sustained depolarization of the neurons are blocked in a time-dependent manner, suggestive of a state-dependent Na channel blocking action
2. incrases the frequency of GABA-A receptor activation & enhances the ability of GABA to induce a flux of Cl into neurons
3. antagonizes the ability of kainate to active the kainate/AMPA substype of excitatory aa (glutamate) |
|
|
Term
Divalproex Na
Pharmacology/Pharmacokinetics |
|
Definition
| inhibits GABA transaminase or succinic semialdehyde dehydrogenase or by inhibition of reuptake by glial cells and nerve endings |
|
|
Term
Diazepam
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Alprazolam
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Lorazepam
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Zolpidem Tartrate
Pharmacology/Pharmacokinetics |
|
Definition
| binds the omega-1 receptor subtype |
|
|
Term
Tramadol HCl
Pharmacology/Pharmacokinetics |
|
Definition
Binding to m-opioid receptors
Inhibition of reuptake of NE & 5HT |
|
|
Term
Propoxyphene Napsylate with Acetaminophen
Pharmacology/Pharmacokinetics |
|
Definition
Acetaminophen inhibits PG synthesis
Propoxyphene napsylate action on the central opiate receptors |
|
|
Term
Oxycodone with Acetaminophen
Pharmacology/Pharmacokinetics |
|
Definition
Acetaminophen inhibits PG synthesis
Oxycodone action on the central opiate receptors |
|
|
Term
Oxycodone HCl (controlled-release)
Pharmacology/Pharmacokinetics |
|
Definition
Oxycodone analgesia action on the central opiate receptors
Respiratory depression
Reduction in motility associated w/ an increase in smooth muscle tone in the antrum of the stomach & duodenum |
|
|
Term
Hydrocodone Bitartrate with Acetaminophen
Pharmacology/Pharmacokinetics |
|
Definition
Acetaminophen inhibits PG synthesis
Hydrocodone Bitartrate action on the central opiate receptors |
|
|
Term
Ibuprofen
Pharmacology/Pharmacokinetics |
|
Definition
Inhibits COX which decreases PG synthesis
PGs are involved in setting the normal set pt in the thermoregulatory center of the hypothalamus |
|
|
Term
Meloxicam
Pharmacology/Pharmacokinetics |
|
Definition
| Inhibits COX which decreases PG synthesis |
|
|
Term
Naproxen
Pharmacology/Pharmacokinetics |
|
Definition
| Inhibits COX which decreases PG synthesis |
|
|
Term
Cyclobenzaprine
Pharmacology/Pharmacokinetics |
|
Definition
| Acts at the brain stem in the CNS; reduction of tonic somatic motor activity influencing both alpha and gamma motorneurons |
|
|
Term
Carisoprodol
Pharmacology/Pharmacokinetics |
|
Definition
Work centrally in the spinal cord or the descending reticular formation to produce muscle relaxation
Metabolite (meprobamate) has sedative & CNS relaxation properties |
|
|
Term
Rosuvastatin Ca
Pharmacology/Pharmacokinetics |
|
Definition
| competitive inhibitor of HMG-CoA |
|
|
Term
Atorvastatin Ca
Pharmacology/Pharmacokinetics |
|
Definition
| competitive inhibitor of HMG-CoA |
|
|
Term
Lovastatin
Pharmacology/Pharmacokinetics |
|
Definition
| competitive inhibitor of HMG-CoA |
|
|
Term
| Simvastatin Pharmacology/Pharmacokinetics |
|
Definition
| competitive inhibitor of HMG-CoA |
|
|
Term
Glipizide
Pharmacology/Pharmacokinetics |
|
Definition
Stimulates insulin synthesis & release from B-cells in the pancreatic islets
Improve binding btw insulin & insulin-receptors
Increase the # of insulin receptors in the periphery |
|
|
Term
Glyburide
Pharmacology/Pharmacokinetics |
|
Definition
Stimulates insulin synthesis & release from B-cells in the pancreatic islets
Improve binding btw insulin & insulin-receptors
Increase the # of insulin receptors in the periphery |
|
|
Term
Pioglitazone HCl
Pharmacology/Pharmacokinetics |
|
Definition
Decreases insulin resistance by improving target cell response to insulin
Bind to PPAR |
|
|
Term
Insulin Glargine, rDNA origin
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Metformin HCl
Dosage Forms |
|
Definition
| Decreases intestinal absorption of glucose, suppresses hepatic gluconeogenesis, and improves insulin sensitivity |
|
|
Term
Fenofibrate
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Lisinopril w/ HCTZ
Pharmacology/Pharmacokinetics |
|
Definition
inhibits ACEI - decreases Ang II - decreases aldosterone
HCTZ inhibits reabsorption of Na and Cl at the DCT |
|
|
Term
Diltiazem HCl
Pharmacology/Pharmacokinetics |
|
Definition
1. Dilates coronary arteries and arterioles
2. inhibits coronary spasm
3. lowers arterial blood pressure
2. slows SA & AV conduction
5. prolongs AV node ERP & FRP
6. Decreasing peripheral resistance |
|
|
Term
Clonidine HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Stimulates alpha-adrenergic - reduced sympathetic outflow from the CNS & a decrease in peripheral resistance, renal vascular resistance, HR, and BP |
|
|
Term
|
Definition
1. decreased HR & CO
2. decrease in systolic & diastolic BP
3. inhibition of isoproterenol tachycardia
4. decrease of reflex orthostatic tachycardia |
|
|
Term
Metoprolol succinate
Pharmacology/Pharmacokinetics |
|
Definition
1. decreased HR & CO
2. decrease in systolic & diastolic BP
3. inhibition of isoproterenol tachycardia
4. decrease of reflex orthostatic tachycardia |
|
|
Term
Metoprolol Tartrate
Pharmacology/Pharmacokinetics |
|
Definition
1. decreased HR & CO
2. decrease in systolic & diastolic BP
3. inhibition of isoproterenol tachycardia
4. decrease of reflex orthostatic tachycardia |
|
|
Term
Carvediolol
Pharmacology/Pharmacokinetics |
|
Definition
1. decreased HR & CO
2. decrease in systolic & diastolic BP
3. inhibition of isoproterenol tachycardia
4. decrease of reflex orthostatic tachycardia |
|
|
Term
Amlodipine Besylate
Pharmacology/Pharmacokinetics |
|
Definition
CCB
1. decrease in peripheral vascular resistance
2. dilation of coronary arteries & arterioles
3. inhibition of coronary spasm |
|
|
Term
Lisinopril
Pharmacology/Pharmacokinetics |
|
Definition
inhibits ACEI - decreases Ang II - decreases aldosterone
ACE is involved w/ the degradation of bradykinin, a vasodilator |
|
|
Term
HCTZ
Pharmacology/Pharmacokinetics |
|
Definition
| inhibits of reabsorption of Na & Cl at the DCT |
|
|
Term
Spironolactone
Pharmacology/Pharmacokinetics |
|
Definition
| competitive antagonism of aldosterone, primarily at the Na/K exchange sites in the DCT |
|
|
Term
Furosemide
Pharmacology/Pharmacokinetics |
|
Definition
| inhibits of reabsorption of Na & Cl at the PCT & DCT |
|
|
Term
Tiotropium Br
Pharmacology/Pharmacokinetics |
|
Definition
| Long-acting antagonist of the action of ACh at the M3 receptor in the smooth muscle of the bronchial tree |
|
|
Term
Levalbuterol HCl
Pharmacology/Pharmacokinetics |
|
Definition
| sympathomimetic which stimulates AC for the formation of c-AMP from ATP |
|
|
Term
Ipratropium Br w/ Albuterol Sulfate
Pharmacology/Pharmacokinetics |
|
Definition
| sympathomimetic which stimulates AC for the formation of c-AMP from ATP |
|
|
Term
Fluticasone Propionate w/ Salmeterol Xinafoate
Pharmacology/Pharmacokinetics |
|
Definition
| sympathomimetic which stimulates AC for the formation of c-AMP from ATP |
|
|
Term
Albuterol Sulfate
Pharmacology/Pharmacokinetics |
|
Definition
| sympathomimetic which stimulates AC for the formation of c-AMP from ATP |
|
|
Term
Montelukast Na
Pharmacology/Pharmacokinetics |
|
Definition
| binds w/ high affinity & selectivity to the CysLT1 receptor where it inhibits physiologic actions of LTD4 w/o any agonist activity |
|
|
Term
Fluticasone Propionate
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Fexofenadine HCl
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Sulfamethoxazole w/ Trimethoprim
Pharmacology/Pharmacokinetics |
|
Definition
Trimethoprim blocks the production of tetrahydrofolic acid by inhibiting the enzyme dihydrofolate reductase
Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competitive antagonism of PABA |
|
|
Term
Amoxicillin Trihydrate
Pharmacology/Pharmacokinetics |
|
Definition
| Inhibits bacterial cell wall synthesis via acylation of the transpeptidase enzyme |
|
|
Term
Azithromycin Dihydrate
Pharmacology/Pharmacokinetics |
|
Definition
| Binds to 50 S ribosomal subunit |
|
|
Term
Pantoprazole Na
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Ranitidine HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Competitively & reversibly inhibits H2 |
|
|
Term
Omeprazole
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Esomeprazole Mg
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
KCl
Pharmacology/Pharmacokinetics |
|
Definition
| Principle intracellular cation |
|
|
Term
Metoclopramide HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Inhibits DA receptors which results in decreased nerve transmission from afferent nerves to the vomiting center threshold |
|
|
Term
ASA
Pharmacology/Pharmacokinetics |
|
Definition
| inhibits PG & TA2 synthesis by acetylating COX |
|
|
Term
Clopidogrel Bisulfate
Pharmacology/Pharmacokinetics |
|
Definition
irreversibly modifying platelet receptors thereby selectively inhibiting the binding of ADP to the receptor
results in inhibition of ADP mediated activation of the GPIIb/IIIa complex and platelet aggregation |
|
|
Term
Warfarin Na
Pharmacology/Pharmacokinetics |
|
Definition
| Antagonizes vit K resulting in a decreased hepatic synthesis of the vit K dependent clotting factors (2, 7, 9, and 10) |
|
|
Term
Prednisone
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Tamsulosin
Pharmacology/Pharmacokinetics |
|
Definition
| Selective alpha adrenergic blocking agent |
|
|
Term
Tolterodine Tartrate
Pharmacology/Pharmacokinetics |
|
Definition
| competitive muscarinic receptor antagonist |
|
|
Term
Alendronate Na
Pharmacology/Pharmacokinetics |
|
Definition
| adheres to sites of bone resorption inhibiting osteoclast activity |
|
|
Term
Levothyroxine Na
Pharmacology/Pharmacokinetics |
|
Definition
1. regulation of growth & development
2. increase in metabolic rate
3. inhibition of the secretion of thyrotropin by the pituitary
4. effects on lipid & carbs metabolism |
|
|
